Form 8-K - Current report:
SEC Accession No. 0001714899-25-000007
Filing Date
2025-01-07
Accepted
2025-01-06 18:13:37
Documents
15
Period of Report
2025-01-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20250106.htm   iXBRL 8-K 31243
2 EX-99.1 exhibit991pressrelease10625.htm EX-99.1 18479
6 image_0.jpg GRAPHIC 13292
  Complete submission text file 0001714899-25-000007.txt   197693

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20250106.xsd EX-101.SCH 1815
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20250106_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20250106_pre.xml EX-101.PRE 12530
17 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20250106_htm.xml XML 2730
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 25512771
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)